Aligos Therapeutics Inc. (ALGS): Price Target Chart

Corporate company logo of Aligos (ALGS)

Aligos Therapeutics (ALGS) exhibits extremely low financial stability, as the business relies exclusively on shareholder investments in the absence of commercial products. Fierce competition within its sector and the probability of clinical trial failures pose serious threats to margins. The quotes shown below, recorded at 36.78, highlight the risks associated with a biotech firm possessing a narrow development portfolio focused solely on liver pathology therapies.

Aligos (ALGS) Price Target Chart: for the period 07/04/2022 - 11/11/2026

Analytical breakdowns for Aligos Therapeutics (ALGS)

- stock value and consensus price forecast:
Stock Price aligos.com|ALGS - Price Target Chart
- stock exchange capitalization data:
Market Value Aligos|ALGS - Enterprise Value
- issuer book value statistics:
Book Value of One Share Aligos Therapeutics|ALGS - Company Book Value|Market Capitalization to Book Value aligos.com|ALGS - Aggregate Company Assets
- debt obligations and liquidity statistics:
Aggregate Debt to Equity Aligos Therapeutics|ALGS - Long-Term Debt to Capital|Ratio of Short-Term Indebtedness to Capital aligos.com|ALGS - Company Aggregate Debts|Debts to Book Capitalization Aligos|ALGS - Company Long-Term Debt|Company Short-Term Loans and Borrowings Aligos Therapeutics|Quick Liquidity Indicator aligos.com
- earnings and market multiples details:
ALGS - Net Profit|Projected Future Earnings Aligos Therapeutics|ALGS - Price to Earnings Ratio|Future Price to Earnings Multiple aligos.com|ALGS - Price/Earnings to Growth Ratio|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Aligos|ALGS - Operating profit EBITDA|Net earnings per share for the last four quarters Aligos Therapeutics|ALGS - Net earnings per share for the last 12 months|Year-over-year earnings per share growth for the last twelve months aligos.com|ALGS - Earnings growth in current year|Expected net earnings per share growth next year Aligos Therapeutics
General company analysis:ALGS Aligos Therapeutics Inc.
Flagship merchandise of Aligos Therapeutics, Inc.

The stable human capital potential of Aligos Therapeutics (ALGS) in virology and hepatology builds the long-term intrinsic value of the asset. The consensus target price reflects a weighted average valuation forecast that neutralizes extreme expert estimates to identify the true fundamental growth trajectory of this biotech company, allowing investors to assess the stock's market potential without the influence of isolated analytical errors.

Competitors of Aligos Therapeutics

Analyst Consensus Forecast arrowheadpharma.com (ARWR)|Price Target Chart Mirum MIRM|Dynavax Technologies Corporation - Price Target Chart|Arbutus - Analyst Consensus Forecast|Analyst Target Range Inventiva Corp (IVA)|Gyre Therapeutics, Inc. (GYRE) - Price Target Chart|ASMB - Analyst Median Target|Price Target Chart Galectin Therapeutics, Inc.|Genfit Corp - Forecast Levels Chart|Analyst Consensus Forecast DRRX|BIVI (biovieinc.com) - Fair Value Consensus|Analyst Consensus Forecast GLMD (Galmed Pharmaceuticals Ltd.)|Analyst Consensus Forecast endrainc.com NDRA|HEPA - Price Target Chart